Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 12.
doi: 10.1007/s00108-025-01963-9. Online ahead of print.

[Empagliflozin-Long-term effects in patients with chronic kidney disease : EMPA-KIDNEY]

[Article in German]
Philipp Scherrer  1   2 , Sirka Nitschmann  3 , Roman-Ulrich Müller  4   5
Affiliations

[Empagliflozin-Long-term effects in patients with chronic kidney disease : EMPA-KIDNEY]

[Article in German]
Philipp Scherrer et al. Inn Med (Heidelb). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Einhaltung ethischer Richtlinien. Interessenkonflikt: P. Scherrer und R.-U. Müller koordinieren die von der Deutschen Forschungsgemeinschaft (DFG) finanzierte STOP-PKD-Studie. S. Nitschmann gibt an, dass kein Interessenkonflikt besteht. Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

References

Literatur

    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105:117–314
    1. Perkovic V et al (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 380:2295–2306 - PubMed
    1. Heerspink HJL, DAPA-CKD Trial Committees and Investigators et al (2020) Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 383:1436–1446 - PubMed
    1. The EMPA-KIDNEY Collaborative Group (2022) Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 388:117–127 - PMC
    1. The EMPA-KIDNEY Collaborative Group (2024) Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocinrol 12:39–50